作者: Corey A. Carter , Scott Z. Caroen , Arnold L. Oronsky , Bryan T. Oronsky
DOI: 10.1159/000441122
关键词:
摘要: Inhibition of vascular endothelial growth factor (VEGF) signaling, an initiator tumor angiogenesis, inhibits and invasion. Bevacizumab, a monoclonal antibody to VEGF, in common use as adjunct standard chemotherapy like irinotecan advanced colorectal cancer, also affects the normal (nontumor) vasculature. Dysphonia or voice changes have been anecdotally reported patients that exposed antiangiogenics. In this case report, we present occurrence severe dysphonia 60-year-old male with metastatic cancer after reintroduction bevacizumab. To our knowledge, is first associated bevacizumab rechallenge.